Aureka Biotechnologies

Aureka Biotechnologies is a tech-bio startup that provides an AI-powered, integrated digital biology platform designed to accelerate the discovery of protein therapeutics. The company utilizes high-throughput technologies, including microfluidics and synthetic biology, to perform rapid generate-test-learn-optimize cycles. By generating large-scale, multi-metric data on therapeutic candidates through single-cell functional screening and geometric protein language models, Aureka aims to transition drug development from empirical trial-and-error methods to a rational, engineering-focused practice.

This platform enables the identification of high-value antibody therapeutics that are otherwise difficult to access via conventional discovery methods. Aureka is applying these capabilities to develop an internal pipeline of differentiated candidates targeting inflammatory and cardiometabolic diseases, while also engaging in strategic partnerships to address complex therapeutic challenges such as receptor agonists and epitope-specific targets. The technology is intended to increase efficiency and reduce costs in the pharmaceutical discovery process, offering potential solutions for difficult drug targets and mechanisms.